Cesar A. Perez, M.D.

Cesar A. Perez, M.D.

Cesar A. Perez, M.D.

Cesar A. Perez, M.D.

  • Assistant Professor of Medicine
James Graham Brown Cancer Center
529 South Jackson Street
Louisville, KY 40202

502-852-2522 - Academic Office
502-562-4370 - Patient Appointments


Clinical Expertise
Hematology; Medical Oncology; Head & Neck and Lung Cancer

 

Board Certifications

  • American Board of Internal Medicine -
    Internal Medicine / Medical Oncology / Hematology

Education and Training

  • Medical School: University of Panama
  • Residency: Rosalind Franklin University of Medicine and Science; Cleveland Clinic Florida
  • Fellowship: University of Miami Sylvester Comprehensive Cancer Center

 

Recent Publications

      • Finnegan TS, Bhatt NH, Shaughnessy JN, Perez C, Redman R, Silverman C, Bumpous J, Potts K, Dunlap NE. Cyclical hypofractionated radiotherapy technique for palliative treatment of locally advanced head and neck cancer: institutional experience and review of palliative regimens. J Community Support Oncol. 2016 Jan;14(1):29-36. doi: 10.12788/jcso.0201. PubMed PMID: 26870840.
      • Khanal S, Joh J, Kwon AM, Zahin M, Perez CA, Dunlap NE, Silverman CL, Tennant PA, Potts KL, Kloecker GH, Bumpous JM, Ghim SJ, Jenson AB, Redman RA. Human papillomavirus E7 serology and association with p16 immunohistochemistry in squamous cell carcinoma of the head and neck. Exp Mol Pathol. 2015 Oct;99(2):335-40. doi: 10.1016/j.yexmp.2015.06.018. Epub 2015 Jun 24. PubMed PMID: 26116154.
      • Wang E, Karedan T, Perez CA. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond. Anticancer Drugs. 2015 Aug;26(7):689-97. doi: 10.1097/CAD.0000000000000247. Review. PubMed PMID: 25974026.
      • Kanaan Z, Kloecker GH, Paintal A, Perez CA. Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond. Onco Targets Ther. 2015 Apr 20;8:885-92. doi: 10.2147/OTT.S67262. eCollection 2015. Review. PubMed PMID: 25945060; PubMed Central PMCID: PMC4408973.
      • Perez CA, Velez M, Raez LE, Santos ES. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation. Lung Cancer. 2014 May;84(2):110-5. doi: 10.1016/j.lungcan.2014.02.001. Epub 2014 Feb 8. Review. PubMed PMID: 24598368.
      • Westin GF, Perez CA, Wang E, Glück S. Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer. Int J Biol Markers. 2013 Sep 27;28(3):233-41. doi: 10.5301/JBM.5000040. PubMed PMID: 23999849.
      • Van Driessche F, Perez CA. Hodgkin lymphoma in pregnancy: achieving the best outcome for both mother and infant. Clin Adv Hematol Oncol. 2013 Aug;11(8):537-8. PubMed PMID: 24518428.
      • Perez CA, Song H, Raez LE, Agulnik M, Grushko TA, Dekker A, Stenson K, Blair EA, Olopade OI, Seiwert TY, Vokes EE, Cohen EE. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep;48(9):887-92. doi: 10.1016/j.oraloncology.2012.03.020. Epub 2012 Apr 17. PubMed PMID: 22513208.
      • Perez CA, Santos ES, Arango BA, Raez LE, Cohen EE. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 2012 May;34(5):736-45. doi: 10.1002/hed.21755. Epub 2011 May 4. Review. PubMed PMID: 21544895.
      • Belalcazar A, Azaña D, Perez CA, Raez LE, Santos ES. Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther. 2012 Apr;12(4):519-28. doi: 10.1586/era.12.16. Review. PubMed PMID: 22500688.